Stem Cell Therapy for Hand and Finger Joint Pain: What to Know Before Treatment in Bangkok

Aching, stiff or swollen hand joints make everyday tasks harder: opening jars, typing, gripping a pen, turning a key. Osteoarthritis (OA) in the base of the thumb and in the finger joints is common, and some people ask whether stem cell therapy is an option. This guide explains what the treatment is, how little research exists for the hand specifically, what first-line care looks like, how the protocol runs at Healthi Life Longevity Center in Bangkok, what it costs, and what to ask before agreeing to treatment.

Stem cell therapy at Healthi Life is a physician-supervised medical protocol, and it is investigational. Outcomes vary and are not guaranteed. A physician confirms eligibility after assessment, and sometimes the answer is no. For the hand, the evidence is thinner than for the knee, and this article says so plainly.

Featured Medical Provider & Leadership

Healthi Life Longevity Center

Center Logo

Center Certificate

Dr. Sarassawadee Suwanjinda, MD (Dr. Petch)

Co-Founder & Chief Medical Strategy Officer

Dr. Napat Hunsajarupan, MD (Dr. First)

Co-Founder & Chief Medical Officer

Overview & Scope

What it is, and what "hand and finger joints" covers

Clinical Evidence

What the research shows

This is the section to read most carefully.

Guidelines do not endorse it for the hand. The 2019 American College of Rheumatology and Arthritis Foundation guideline strongly recommends against stem cell injections for knee and hip OA. For hand OA it states that stem cell injections have not been evaluated, so it makes no recommendation either way (Kolasinski et al., 2020). "No recommendation" is not approval; it means the evidence was not there.

We found no randomized trial of umbilical cord MSCs in hand or finger OA. The study closest to the question is small and uses a different product. A 2025 retrospective series reviewed 30 hands of 19 people with thumb CMC arthritis, stages 1 to 4, who received an injection of a mixture of stromal vascular fraction, fat-derived stem cells and platelet-rich plasma under X-ray guidance. The authors concluded that the injection helped improve pain symptoms and might postpone surgery that removes part of the joint (Pumberger et al., 2025). A retrospective series without a comparison group cannot show that the injection caused the improvement, and the cells came from the person's own fat, not from umbilical cord.

For the knee, evidence is larger but still mixed. A 2026 network meta-analysis of 24 randomized trials found that the gains from injected orthobiologics, including umbilical cord MSCs, did not exceed the minimal clinically important difference up to 12 months when compared with hyaluronic acid (Han et al., 2026). That finding is about knees, but it shows why caution applies to the smaller hand joints, where data are scarcer. A provider who tells you otherwise should be able to show you the studies.

Candidacy & Governance

Who may be a candidate, and who may not

A physician decides after assessment. People who may be considered generally have confirmed hand or finger OA, persistent pain that limits daily life, and have already tried first-line care.

A physician may advise against treatment when:

• Your pain may have another cause, such as inflammatory arthritis, a tendon problem, nerve compression (for example, carpal tunnel syndrome) or gout, which need different care. A proper diagnosis comes first.
• You have an active infection, an inflamed joint of unclear cause, or a medical history that raises risk.
• You have not tried first-line options such as hand exercises, a thumb-base splint or topical anti-inflammatory gel.
• You expect a guaranteed result or a reversal of joint changes.
• Your joint damage is advanced enough that a hand surgeon should assess you first.

A "no" is a normal outcome of a responsible assessment. The center describes its model as governance-first: eligibility screening comes before approval, and not every guest qualifies.

Standard of Care

Alternatives and first-line care

Treatments with stronger evidence exist for hand OA, and they come first.

The 2018 EULAR recommendations for hand OA (published 2019) include five overarching principles and ten recommendations. The first three cover non-drug options: education, assistive devices, exercises and orthoses (splints). Topical NSAIDs are the preferred first choice among medicines, with oral NSAIDs for a limited duration, chondroitin sulfate for symptom relief, and intra-articular glucocorticoids generally not recommended except possibly for painful interphalangeal OA. Disease-modifying drugs and biologics are discouraged for hand OA, and surgery is considered when other care fails (Kloppenburg et al., 2019).

The ACR and Arthritis Foundation guideline similarly gives a strong recommendation for hand orthoses for first CMC (thumb base) OA, and conditional recommendations for orthoses for other hand joints, topical NSAIDs, intra-articular steroid injections and chondroitin sulfate for hand OA (Kolasinski et al., 2020).

In practice, a sensible plan often combines hand exercises, a splint for the thumb base, joint-protection habits (wider-grip tools, jar openers), topical or oral medicine chosen with your own doctor, and a hand surgeon's opinion if function keeps falling. Stem cell therapy, where it is used, is an addition after assessment, not a substitute.

Treatment Journey

How the protocol runs at Healthi Life

Ask for the injection technique, any imaging guidance, expected hand use in the days after treatment, and the visit schedule in writing.

Pricing Transparency

Published prices

Every treatment listed here is dispensed only after a medical consultation at Healthi Life and on a physician's prescription. Prices are published for transparency, not as an offer to supply.

Shoulder, hand and finger joints use the same per-joint grid as the knee. Dose is confirmed by a physician after assessment. Cells are UC-MSC, administered fresh, with a Certificate of Analysis per batch.

The published two-joint price (?155,000, about $5,000, for 5 million cells in each of two joints) is listed for two knees. If you are considering more than one hand or finger joint, ask the team to confirm the total in writing, joint by joint, before you book travel. Prices are per joint, so the number of joints matters a great deal to the total.

Safety & Considerations

Risks and limits of the evidence

If you are harmed after a product marketed as regenerative medicine, the FDA asks U.S. consumers to report through MedWatch. Also tell your treating physician.

Checklist

Questions to ask before treatment

The International Society for Stem Cell Research (ISSCR) also publishes The ISSCR Guide to Stem Cell Treatments, with a "What to Ask Your Doctor" section.

Some guests also book the Advanced Check-Up (?30,000, 90+ biomarkers, all-inclusive, no separate lab fees) as a baseline. That baseline is what a longer-term longevity program with physician follow-up is built on.

Patient Inquiries

Frequently asked questions

Next Steps & Consultation

Take the Next Step: Request Your Medical Evaluation

Request a complimentary 20-minute Discovery Consultation with the medical team at Healthi Life Longevity Center. Share your recent imaging reports, lab results, and treatment history to determine if you meet the eligibility criteria for Hand Joint Pain Treatment in Bangkok Thailand.